A novel pharmacological entity toward integrated multimodal immunotherapy

Rafael Sirera; Manuel Beltrán-Visiedo; Lorenzo Galluzzi

doi:10.1016/j.tips.2024.12.001

A novel pharmacological entity toward integrated multimodal immunotherapy

Rafael Sirera, Manuel Beltrán-Visiedo, Lorenzo Galluzzi

Cancer Signaling and Microenvironment (CSM)

Fox Chase Cancer Center

Research output: Contribution to journal › Article › peer-review

Abstract

Most solid tumors are insensitive to single-agent immunotherapy, calling for the development of combinatorial treatment regimens. Recently, Lin and collaborators developed a pharmacological platform enabling the combination of different immunotherapies into a single chemical entity. This approach may effectively circumvent obstacles associated with the simultaneous delivery of multiple immunotherapeutic agents.

Original language	English
Pages (from-to)	95-97
Number of pages	3
Journal	Trends in Pharmacological Sciences
Volume	46
Issue number	2
DOIs	https://doi.org/10.1016/j.tips.2024.12.001
State	Published - Feb 2025

Keywords

CD8 cytotoxic T lymphocyte
dendritic cell
immune checkpoint inhibitor
immunoevasion
multimodal targeting chimera
triple orthogonal linker
Neoplasms/therapy
Animals
Immunotherapy/methods
Humans
Combined Modality Therapy

Access to Document

10.1016/j.tips.2024.12.001

Cite this

@article{4bb7edd5ee76467d9f3e2cd4ba364e3d,

title = "A novel pharmacological entity toward integrated multimodal immunotherapy",

abstract = "Most solid tumors are insensitive to single-agent immunotherapy, calling for the development of combinatorial treatment regimens. Recently, Lin and collaborators developed a pharmacological platform enabling the combination of different immunotherapies into a single chemical entity. This approach may effectively circumvent obstacles associated with the simultaneous delivery of multiple immunotherapeutic agents.",

keywords = "CD8 cytotoxic T lymphocyte, dendritic cell, immune checkpoint inhibitor, immunoevasion, multimodal targeting chimera, triple orthogonal linker, Neoplasms/therapy, Animals, Immunotherapy/methods, Humans, Combined Modality Therapy",

author = "Rafael Sirera and Manuel Beltr{\'a}n-Visiedo and Lorenzo Galluzzi",

year = "2025",

month = feb,

doi = "10.1016/j.tips.2024.12.001",

language = "English",

volume = "46",

pages = "95--97",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

publisher = "Elsevier Ltd.",

number = "2",

}

TY - JOUR

T1 - A novel pharmacological entity toward integrated multimodal immunotherapy

AU - Sirera, Rafael

AU - Beltrán-Visiedo, Manuel

AU - Galluzzi, Lorenzo

PY - 2025/2

Y1 - 2025/2

N2 - Most solid tumors are insensitive to single-agent immunotherapy, calling for the development of combinatorial treatment regimens. Recently, Lin and collaborators developed a pharmacological platform enabling the combination of different immunotherapies into a single chemical entity. This approach may effectively circumvent obstacles associated with the simultaneous delivery of multiple immunotherapeutic agents.

AB - Most solid tumors are insensitive to single-agent immunotherapy, calling for the development of combinatorial treatment regimens. Recently, Lin and collaborators developed a pharmacological platform enabling the combination of different immunotherapies into a single chemical entity. This approach may effectively circumvent obstacles associated with the simultaneous delivery of multiple immunotherapeutic agents.

KW - CD8 cytotoxic T lymphocyte

KW - dendritic cell

KW - immune checkpoint inhibitor

KW - immunoevasion

KW - multimodal targeting chimera

KW - triple orthogonal linker

KW - Neoplasms/therapy

KW - Animals

KW - Immunotherapy/methods

KW - Humans

KW - Combined Modality Therapy

UR - https://www.scopus.com/pages/publications/85212980765

U2 - 10.1016/j.tips.2024.12.001

DO - 10.1016/j.tips.2024.12.001

M3 - Article

C2 - 39721827

AN - SCOPUS:85212980765

SN - 0165-6147

VL - 46

SP - 95

EP - 97

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

IS - 2

ER -

A novel pharmacological entity toward integrated multimodal immunotherapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this